Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles
 

Open Access

Technical Note

EJMCM. 2015; 2(2): 57-


A newly human developed diabody against CD99 delivers a lethal signal through p53 pathway reactivation in Ewing sarcoma cells and synergistically acts with doxorubicin

Katia Scotlandi, Clara Guerzoni, Valentina Fiori, Cristina Manara, Michela Pasello, Diego Moricoli, Mara Gellini, Maurizio Cianfriglia, Mauro Magnani.

Abstract
Ewing sarcoma is the second most frequent primary tumor of bone, preferentially occurring in children and adolescents. Despite significant improvements have been achieved in localized tumors thanks to dose intensification of chemotherapy, outcome of patients with metastasis at diagnosis remains grim. In addition, even in the most favorable situations, patients must face with important side effects which significantly impact their quality of life. Either scientific and patient communities are now very sensitive on the need of new drugs, which may reduce chemotherapy toxicity while maintaining effectiveness of current regimens. We present here a new engeneered human bivalent single chain fragment variable diabody (C7 scFv diabody) directed against CD99, a transmembrane protein whose high expression characterizes Ewing sarcoma. The triggering of CD99 with C7scFv diabody induces rapid and massive Ewing sarcoma cell death through MDM2 ubiquitination and p53 reactivation. Accordingly, the most CD99-responsive Ewing sarcoma cells have transcriptional active p53 and greatly benefit from MDM2 degradation. CD99 triggering also potentiates the cytotoxic effect of doxorubicin in vitro and in vivo and reactivates p53 to a much greater degree, which in turn markedly increased expression of pro-apoptosis genes. Evaluation of Ki-67 labelling and apoptosis rate by TUNEL confirms the efficacy of the treatment in xenografts.

Key words: In contrast, mesenchymal stem cells, though expressing high levels of CD99, show no p53 activation and escape death induced by CD99 C7scFv diabody. No sign of toxicity was observed in mice treated with anti-CD99 scFV C7 diabody. Overall, our data provide the rationale for the use of this newly developed anti-CD99 diabody in the treatment of patients with Ewing sarcoma.



Similar Articles

Passive social media use and psychological well-being during the COVID-19 pandemic: The role of social comparison and emotion regulation.
Yue Z, Zhang R, Xiao J
Computers in human behavior. 2022; 127(): 107050

The promise of neuroprotection by dietary restriction in glaucoma.
Russo R, Nucci C, Adornetto A
Neural regeneration research. 2022; 17(1): 45-47

Biovalue in Human Brain Banking: Applications and Challenges for Research in Neurodegenerative Diseases.
Vedam-Mai V
Methods in molecular biology (Clifton, N.J.). 2022; 2389(): 209-220

Using the Health Belief Model to examine travelers' willingness to vaccinate and support for vaccination requirements prior to travel.
Suess C, Maddock J, Dogru T, Mody M, Lee S
Tourism management. 2022; 88(): 104405

Occupant health in buildings: Impact of the COVID-19 pandemic on the opinions of building professionals and implications on research.
Awada M, Becerik-Gerber B, White E, Hoque S, O'Neill Z, Pedrielli G, Wen J, Wu T
Building and environment. 2022; 207(): 108440


Full-text options


Latest Statistics about COVID-19
• pubstat.org


Add your Article(s) to Indexes
• citeindex.org






Covid-19 Trends and Statistics
ScopeMed.com
CiteIndex.org
CancerLine
FoodsLine
PhytoMedline
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright ScopeMed Information Services.



ScopeMed Web Sites